NASDAQ:INDP Indaptus Therapeutics (INDP) Stock Price, News & Analysis $5.40 -0.75 (-12.20%) Closing price 09/3/2025 03:59 PM EasternExtended Trading$5.70 +0.30 (+5.63%) As of 09/3/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Indaptus Therapeutics Stock (NASDAQ:INDP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Indaptus Therapeutics alerts:Sign Up Key Stats Today's Range$5.40▼$6.4050-Day Range$5.40▼$12.8752-Week Range$5.40▼$58.24Volume23,588 shsAverage Volume6,222 shsMarket Capitalization$5.99 millionP/E RatioN/ADividend YieldN/APrice Target$238.00Consensus RatingBuy Company Overview Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. Read More Indaptus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreINDP MarketRank™: Indaptus Therapeutics scored higher than 49% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingIndaptus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIndaptus Therapeutics has received no research coverage in the past 90 days.Read more about Indaptus Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Indaptus Therapeutics are expected to grow in the coming year, from ($1.79) to ($1.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Indaptus Therapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Indaptus Therapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.07% of the float of Indaptus Therapeutics has been sold short.Short Interest Ratio / Days to CoverIndaptus Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Indaptus Therapeutics has recently increased by 64.04%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIndaptus Therapeutics does not currently pay a dividend.Dividend GrowthIndaptus Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.07% of the float of Indaptus Therapeutics has been sold short.Short Interest Ratio / Days to CoverIndaptus Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Indaptus Therapeutics has recently increased by 64.04%, indicating that investor sentiment is decreasing significantly. News and Social Media1.4 / 5News Sentiment-0.50 News SentimentIndaptus Therapeutics has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Indaptus Therapeutics this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Indaptus Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Indaptus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders20.80% of the stock of Indaptus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.06% of the stock of Indaptus Therapeutics is held by institutions.Read more about Indaptus Therapeutics' insider trading history. Receive INDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INDP Stock News HeadlinesIndaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment ConferenceSeptember 2 at 4:05 PM | globenewswire.comIndaptus Therapeutics files $200M mixed securities shelfAugust 14, 2025 | msn.comWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now. | Stansberry Research (Ad)Indaptus Therapeutics reports Q2 EPS ($9.09) vs ($13.16) last yearAugust 13, 2025 | msn.comIndaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 13, 2025 | globenewswire.comIndaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and WarrantsJuly 1, 2025 | globenewswire.comIndaptus Therapeutics Announces Reverse Stock Split - FinanzNachrichten.deJune 26, 2025 | finanznachrichten.deIndaptus Therapeutics, Inc. Announces One-for-Twenty-Eight Reverse Stock Split to Enhance Nasdaq Compliance and Attract InvestorsJune 26, 2025 | nasdaq.comSee More Headlines INDP Stock Analysis - Frequently Asked Questions How have INDP shares performed this year? Indaptus Therapeutics' stock was trading at $23.5788 at the start of the year. Since then, INDP stock has decreased by 77.1% and is now trading at $5.40. How were Indaptus Therapeutics' earnings last quarter? Indaptus Therapeutics, Inc. (NASDAQ:INDP) issued its earnings results on Wednesday, August, 13th. The company reported ($9.09) EPS for the quarter, missing the consensus estimate of ($0.36) by $8.73. When did Indaptus Therapeutics' stock split? Shares of Indaptus Therapeutics reverse split before market open on Friday, June 27th 2025.A 1-28 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 26th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Indaptus Therapeutics? Shares of INDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Indaptus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Indaptus Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), GE Aerospace (GE), Meta Platforms (META), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings8/13/2025Today9/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INDP CIK1857044 Webintecpharma.com Phone(646) 427-2727Fax972-2586-9176Employees6Year FoundedN/APrice Target and Rating Average Price Target for Indaptus Therapeutics$238.00 High Price Target$336.00 Low Price Target$140.00 Potential Upside/Downside+4,123.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($37.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.02 million Net MarginsN/A Pretax MarginN/A Return on Equity-612.59% Return on Assets-243.78% Debt Debt-to-Equity RatioN/A Current Ratio0.75 Quick Ratio0.75 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.51) per share Price / Book-3.73Miscellaneous Outstanding Shares1,110,000Free Float877,000Market Cap$6.25 million OptionableNot Optionable Beta1.27 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:INDP) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INDP Stock Alerts